Rating Watching: Is It Finally Time? Benchmark Starts Coverage On Heska Corp (NYSE:HSKA) with $78.00 Price Target

November 29, 2016 - By Ellis Scott

Rating Watching: Is It Finally Time? Benchmark Starts Coverage On Heska Corp (NYSE:HSKA) with $78.00 Price Target

Why Benchmark Gives Heska Corp (NYSE:HSKA) $78.00 Price Target

Benchmark analyst has begun coverage on Heska Corp (NYSE:HSKA) with a $78.00 target and “Buy” rating. The target suggests a potential upside of 15.25% from company’s last stock price.

Heska Corp (NASDAQ:HSKA) Ratings Coverage

Out of 2 analysts covering Heska Corp (NYSE:HSKA), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. $53 is the highest target while $33.25 is the lowest. The $53 average target is -21.50% below today’s ($67.52) stock price. Heska Corp has been the topic of 3 analyst reports since November 12, 2015 according to StockzIntelligence Inc. Sidoti initiated Heska Corp (NASDAQ:HSKA) on Friday, July 1 with “Buy” rating. The firm has “Neutral” rating given on Wednesday, September 21 by B. Riley & Co. The rating was maintained by B. Riley & Co with “Neutral” on Thursday, November 12.

About 113,084 shares traded hands or 11.16% up from the average. Heska Corp (NYSE:HSKA) has risen 132.87% since April 26, 2016 and is uptrending. It has outperformed by 127.61% the S&P500.

Analysts await Heska Corp (NASDAQ:HSKA) to report earnings on March, 2. They expect $0.37 earnings per share, up 32.14% or $0.09 from last year’s $0.28 per share. HSKA’s profit will be $2.53M for 45.62 P/E if the $0.37 EPS becomes a reality. After $0.45 actual earnings per share reported by Heska Corp for the previous quarter, Wall Street now forecasts -17.78% negative EPS growth.

Insitutional Activity: The institutional sentiment decreased to 1.36 in Q2 2016. Its down 0.18, from 1.54 in 2016Q1. The ratio dived, as 6 funds sold all Heska Corp shares owned while 29 reduced positions. 24 funds bought stakes while 30 increased positions. They now own 4.56 million shares or 4.63% more from 4.36 million shares in 2016Q1.

Blackrock Institutional Tru Na has invested 0% of its portfolio in Heska Corp (NASDAQ:HSKA). Metropolitan Life Insur owns 4,853 shares or 0% of their US portfolio. New York State Common Retirement Fund accumulated 5,800 shares or 0% of the stock. Blackrock Japan has 709 shares for 0% of their US portfolio. Tfs Cap Ltd last reported 33,124 shares in the company. Ranger Inv Management Ltd Partnership last reported 0.15% of its portfolio in the stock. Bankshares Of Montreal Can has invested 0% of its portfolio in Heska Corp (NASDAQ:HSKA). Deutsche Bancorporation Ag has invested 0% of its portfolio in Heska Corp (NASDAQ:HSKA). Oxford Asset Management holds 60,215 shares or 0.09% of its portfolio. Geode Capital Limited Liability last reported 43,308 shares in the company. The Massachusetts-based Loomis Sayles And Company Limited Partnership has invested 0% in Heska Corp (NASDAQ:HSKA). Nationwide Fund last reported 3,833 shares in the company. California Public Employees Retirement accumulated 0% or 6,880 shares. Landscape Management Lc last reported 8,510 shares in the company. Moreover, Teachers Incorporated has 0% invested in Heska Corp (NASDAQ:HSKA) for 9,129 shares.

Insider Transactions: Since July 1, 2016, the stock had 0 buys, and 15 sales for $6.68 million net activity. 9,998 shares were sold by McGinley Michael J, worth $601,051 on Monday, November 7. Shares for $423,666 were sold by Wilson Kevin S.. NAPOLITANO JASON A sold 20,000 shares worth $820,000. Another trade for 5,000 shares valued at $324,258 was made by Lippincott Rod on Tuesday, November 22. McMahon John sold $7,028 worth of stock or 137 shares. $305,000 worth of Heska Corp (NASDAQ:HSKA) shares were sold by Asakowicz Steve.

Heska Corporation develops, manufactures, markets, sells and supports veterinary products. The company has a market cap of $461.86 million. The Firm focuses on the canine and feline companion animal health markets. It has a 54.48 P/E ratio. The Company’s divisions include Core Companion Animal Health segment, which includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, and single use services and products, such as heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing, and Other Vaccines, Pharmaceuticals and Products segment, which includes private label vaccine and pharmaceutical production, primarily for cattle but also for other animals, including small mammals.

According to Zacks Investment Research, “Heska Corporation is focused on the discovery, development and marketing of companion animal health products. In addition to manufacturing certain of companion animal products, the company’s primary manufacturing subsidiary, Diamond Animal Health, Inc., also manufactures animal health vaccine products which are marketed and distributed by third parties. In addition to manufacturing veterinary allergy products for marketing and sale by the company, subsidiaries, Center Laboratories, Inc. and CMG-Heska Allergy Products S.A., also manufacture and sell human allergy products.”

HSKA Company Profile

Heska Corporation, incorporated on March 27, 1997, develops, makes, markets, sells and supports veterinary products. The Firm is focused on the canine and feline companion animal health markets. The Firm operates in two divisions, which include Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, and single use services and products, such as heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing. The OVP segment includes private label vaccine and pharmaceutical production, primarily for cattle but also for other animals, including small mammals. It sells veterinary diagnostic and other specialty veterinary products. The Company’s offerings include blood testing instruments and supplies, digital imaging products, software and services, and single use services and products, such as in-clinic heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing.

Another recent and important Heska Corp (NASDAQ:HSKA) news was published by Marketwatch.com which published an article titled: “Heska downgraded to neutral from buy at B. Riley” on December 21, 2009.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>